WILMINGTON, Del. — The Innovation Space™ today announced the ten startups selected for the Fall 2026 Science Inc.™ | Life Sciences cohort. Together, their work spans therapeutics, drug delivery platforms and medical technologies addressing a range of significant health challenges.
The 14-week accelerator helps early-stage life science startups prepare for their next capital raise by strengthening their commercialization strategies, sharpening their value propositions and building investor readiness. Through sector-specific programming and individualized support, founders work with Entrepreneurs-in-Residence, commercialization experts, technical advisers, mentors and investors to deepen their understanding of their markets, refine their business models and communicate a clear, compelling case for investment.
“Life sciences founders must continually decide where to focus their time and resources across research strategy, regulatory pathways, market development and access to capital, often while managing all of them at once,” said Bill Provine, president and CEO of The Innovation Space. “The companies in this Science Inc. cohort are tackling significant health challenges through a range of promising scientific approaches. The program provides these founders with practical insights and valuable networks to help them set clear priorities, sharpen their commercialization strategies and build a stronger path from scientific promise to real-world impact.”
The Fall 2026 program will address key considerations for emerging life sciences companies, including market and customer validation, clinical and regulatory strategy, intellectual property, fundraising, investor communications and preparing materials for investor due diligence. Founders will also receive individualized feedback as they apply insights from the program directly to their companies.
The ten companies selected for the Fall 2026 cohort are:
AddGraft is developing a skin cell therapy platform to create novel treatments for rare diseases, substance use disorders and other conditions.
Brainstorm Therapeutics combines patient-derived human brain organoids and AI to discover disease-modifying therapies for neurological diseases.
Diapin Therapeutics is advancing drug candidates for cardiovascular and metabolic conditions, including stroke, myocardial infarction and metabolic disorders.
Glow Therapeutics is developing a theragnostic oncology drug delivery platform for peritoneal cancers, combining therapeutic and diagnostic approaches to support targeted treatment.
GlycoX is developing metabolic health solutions focused on improving glucose control and supporting healthier metabolic function.
Hayflick Therapeutics is developing therapies focused on cellular aging, including a localized approach targeting the mTOR pathway.
Hera Health Solutions is developing a nanotechnology-enabled platform for advanced pharmaceutical reformulation, with a focus on scalable and reproducible drug development and manufacturing.
Odycell is developing a bioactive nanoparticle platform that reprograms the tumor ecosystem.
Treysta Medical Technologies is developing technology aimed at preventing scars, contractures and pathological fibrosis, including applications in serious burn care.
The tenth company is operating in stealth mode while developing a novel therapy for tissue regeneration.
With the Fall 2026 cohort, Science Inc. has now supported more than 100 startups across life sciences, clean technology, and advanced materials. Science Inc. is organized into dedicated Life Sciences and CleanTech & Materials cohorts, giving founders access to programming, expertise and connections aligned with the distinct commercialization and capital-readiness challenges in their sectors. The primarily virtual accelerator brings together founders from across the United States and internationally for individualized coaching, investor preparation and connections to The Innovation Space’s broader network of mentors, investors and industry leaders. Participating companies retain ownership and equity in their businesses.
About The Innovation Space™
The Innovation Space™ is a nonprofit innovation ecosystem and the virtual and physical home for science-based startups. Located at the Experimental Station in Wilmington, Delaware, The Innovation Space helps founders commercialize, grow and scale companies in life sciences, clean tech and advanced materials.
Startups have access to 130,000 square feet of state-of-the-art lab and office space, cutting-edge equipment, funding opportunities, accelerator and mentorship programs, and a collaborative community of entrepreneurs, investors, industry leaders and advisers. Together, these resources help founders move scientific innovations toward the market and meaningful real-world impact.
Learn more at innovationspace.org and subscribe to The Innovation Space newsletter for updates on programs, funding opportunities and community milestones.